tiprankstipranks
Sangamo Biosciences (SGMO)
NASDAQ:SGMO

Sangamo Biosciences Stock Analysis & Ratings

SGMO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.48 - $12.83
Previous Close$3.95
Volume311.00
Average Volume (3M)1.35M
Market Cap$575.75M
P/E Ratio-3.3
Beta1.61
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.21


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

SGMO FAQ

What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $3.48 and its highest was $12.83 in the past 12 months.
    What is Sangamo Biosciences’s market cap?
    Sangamo Biosciences’s market cap is $575.75M.
      What is Sangamo Biosciences’s price target?
      The average price target for Sangamo Biosciences is $14.28. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $25.00 ,the lowest forecast is $4.40. The average price target represents 263.82% Increase from the current price of $3.925.
        What do analysts say about Sangamo Biosciences?
        Sangamo Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Sangamo Biosciences’s upcoming earnings report date?
          Sangamo Biosciences’s upcoming earnings report date is Aug 10, 2022 which is in 84 days.
            How were Sangamo Biosciences’s earnings last quarter?
            Sangamo Biosciences released its earnings results on May 05, 2022. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.311 by $0.011.
              Is Sangamo Biosciences overvalued?
              According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
                Does Sangamo Biosciences pay dividends?
                Sangamo Biosciences does not currently pay dividends.
                What is Sangamo Biosciences’s EPS estimate?
                Sangamo Biosciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Sangamo Biosciences have?
                Sangamo Biosciences has 146,690,000 shares outstanding.
                  What happened to Sangamo Biosciences’s price movement after its last earnings report?
                  Sangamo Biosciences reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.311. Following the earnings report the stock price went down -3.721%.
                    Which hedge fund is a major shareholder of Sangamo Biosciences?
                    Among the largest hedge funds holding Sangamo Biosciences’s share is Platinum Investment Management. It holds Sangamo Biosciences’s shares valued at 1M.

                      ---

                      Sangamo Biosciences Stock Analysis

                      The Sangamo Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Sangamo Biosciences

                      Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Roche Holding
                      Ligand Pharma
                      RegenXBio
                      Editas Medicine

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis